166 related articles for article (PubMed ID: 12602762)
61. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
Bundred N; Howell A
Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
[TBL] [Abstract][Full Text] [Related]
62. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro.
Simard J; Labrie C; Bélanger A; Gauthier S; Singh SM; Mérand Y; Labrie F
Int J Cancer; 1997 Sep; 73(1):104-12. PubMed ID: 9334816
[TBL] [Abstract][Full Text] [Related]
63. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
64. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer.
Nicholson RI; Gee JM; Manning DL; Wakeling AE; Montano MM; Katzenellenbogen BS
Ann N Y Acad Sci; 1995 Jun; 761():148-63. PubMed ID: 7625718
[No Abstract] [Full Text] [Related]
65. Chemoprevention with aromatase inhibitors--trial strategies.
Goss PE; Strasser K
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):143-9. PubMed ID: 11850218
[TBL] [Abstract][Full Text] [Related]
66. In vitro effects of oestrogens, antioestrogens and SERMs on pancreatic solid pseudopapillary neoplasm-derived primary cell culture.
Tognarini I; Tonelli F; Nesi G; Martineti V; Galli G; Gozzini A; Colli E; Zonefrati R; Paglierani M; Marini F; Sorace S; Cavalli T; Cavalli L; Tanini A; Brandi ML
Cell Oncol; 2010; 32(5-6):331-43. PubMed ID: 20364070
[TBL] [Abstract][Full Text] [Related]
67. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
68. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
Planta Med; 2001 Aug; 67(6):510-4. PubMed ID: 11509969
[TBL] [Abstract][Full Text] [Related]
69. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
70. The anti-estrogen hydroxytamoxifen is a potent antagonist in a novel yeast system.
Liu JW; Jeannin E; Picard D
Biol Chem; 1999 Nov; 380(11):1341-5. PubMed ID: 10614829
[TBL] [Abstract][Full Text] [Related]
71. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators.
Fuchs-Young R; Howe S; Hale L; Miles R; Walker C
Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075
[TBL] [Abstract][Full Text] [Related]
72. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
73. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
[TBL] [Abstract][Full Text] [Related]
74. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
75. Recent advances in selective estrogen receptor modulators for breast cancer.
Wang T; You Q; Huang FS; Xiang H
Mini Rev Med Chem; 2009 Sep; 9(10):1191-201. PubMed ID: 19817711
[TBL] [Abstract][Full Text] [Related]
76. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
[TBL] [Abstract][Full Text] [Related]
77. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
[TBL] [Abstract][Full Text] [Related]
78. Prevention of breast cancer: current state of the science and future opportunities.
Uray IP; Brown PH
Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
[TBL] [Abstract][Full Text] [Related]
79. [Status of novel bone-targeting SERMs in development].
Ohta H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():433-41. PubMed ID: 18161145
[No Abstract] [Full Text] [Related]
80. Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-α.
Ma Y; Tomita Y; Preet A; Clarke R; Englund E; Grindrod S; Nathan S; De Oliveira E; Brown ML; Rosen EM
Mol Endocrinol; 2014 Dec; 28(12):1971-86. PubMed ID: 25264941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
